Tempramed rolls out products to pharmacies in Israel

Executive Summary

• Tempramed Technologies has completed initial sales of its temperature-protection product portfolio (Vivi Cap, Vivi Cap Smart, Vivi Epi, and Vivi Med) to Maccabi Healthcare Services, Israel's second-largest health maintenance organization.
• The company has launched a national in-pharmacy marketing campaign to place its products on shelves across Maccabi's brick-and-mortar pharmacy network, marking the first time the products are sold to customers in-store and online.
• This rollout provides broad patient access to Tempramed's solutions for temperature-sensitive medications (such as insulin and epinephrine) to over 2.8 million insured members, signaling a transition from agreement to active commercial execution.

Key Details

• Product Sales: Initial sales completed for Vivi Cap, Vivi Cap Smart, Vivi Epi, and Vivi Med.
• Partner: Maccabi Healthcare Services, serving over 2.8 million insured members nationwide.
• Distribution Channel: National rollout across Maccabi's brick-and-mortary pharmacy network in Israel, including both in-store and online sales.
• Strategic Impact: Marks the first instance of Tempramed products being sold directly to customers in a retail pharmacy setting.
• Target Audience: Patients managing temperature-sensitive medications, specifically insulin and epinephrine auto-injectors.
• Future Outlook: Management views this as a step toward driving recurring demand and expanding to additional Health Maintenance Organizations (HMOs), payers, and institutional partners.

Notable Quotes

• "This is an important operational and commercialization milestone for Tempramed as this is the first time our products will be sold to customers in store and on-line... Shipping product and launching a nationwide campaign across the Maccabi brick-and-mortar pharmacy network demonstrates our ability to execute at scale within a large health care system." — Ron Nagar, Chief Executive Officer